Brandon Couillard, an analyst from Wells Fargo, maintained the Hold rating on Danaher. The associated price target is $205.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Couillard’s rating is based on a combination of factors that reflect both potential and caution for Danaher’s future performance. The company reported a solid earnings beat for the second quarter of 2025, with a positive outlook for the bioprocess segment, which has shown consistent growth. However, the equipment part of this segment faced challenges due to tariffs, although management is optimistic about future improvements.
Despite the positive developments, there are underlying concerns that contribute to the Hold rating. The life sciences segment has experienced prolonged periods of low or negative growth, and while there is an expectation of improvement in the second half of the year, the assumptions may be optimistic. Additionally, the company’s guidance for 2025 reflects a cautious approach, with a modest increase in EPS estimates and a revised price target that suggests limited upside compared to peers. These mixed signals lead to a balanced view, resulting in the Hold recommendation.
According to TipRanks, Couillard is a 5-star analyst with an average return of 13.7% and a 58.00% success rate. Couillard covers the Healthcare sector, focusing on stocks such as Exact Sciences, Thermo Fisher, and Maravai Lifesciences Holdings.